NEW YORK, NY / ACCESS Newswire / January 29, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract ...

Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new trial, adding to growing threats to the Danish company’s early ...

Novo Nordisk was harshly criticized by a U.K. trade group for violating voluntary codes and discrediting the pharmaceutical industry over a failure to properly disclose payments to health and ...

Novo Nordisk has been one of the chief beneficiaries of the boom in GLP-1 drugs, which have shown great promise in fighting obesity. Competition in the space is fierce, but shares got a much ...

Novo Nordisk shares rose sharply Friday after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their body weight in a clinical trial. Shares were 7 ...

Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news Novo ...

Total gross spending on all three topped $14 billion, it said. Shares in Novo Nordisk were already down before the publication of the list due to new obesity data but fell further on the release ...

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

Pfizer’s top-selling breast cancer drug Ibrance also on list Drugmakers plan to ask Trump administration to pause talks The ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

Novo Nordisk NOVO.B9.60%increase; green up pointing triangle shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot showed patients lost 22% of their ...